PMID- 32723508
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
VI  - 40
IP  - 3
DP  - 2021 Mar
TI  - MiRNAs profile as biomarkers of nutritional therapy for the prevention of type 2 
      diabetes mellitus: From the CORDIOPREV study.
PG  - 1028-1038
LID - S0261-5614(20)30350-2 [pii]
LID - 10.1016/j.clnu.2020.06.035 [doi]
AB  - BACKGROUND AND AIM: The incidence of type 2 diabetes mellitus (T2DM) has 
      increased worldwide. One of the first actions to reduce the risk of this disease 
      is to implement healthy dietary models; however, no universal dietary strategies 
      have so far been established. In addition, MicroRNAs (miRNAs) are emerging as new 
      biomarkers to predict disease. We aimed to study whether miRNAs could be used to 
      select the nutritional therapy to prevent T2DM development in patients with 
      cardiovascular disease. METHODS: All patients from the CORDIOPREV study without 
      T2DM at baseline according to the American Diabetes Association (ADA) diagnostic 
      criteria (n = 462) were included in the present study. Of them, after a median 
      dietary intervention period of 60 months with two diets (Low fat or Mediterranean 
      diets), 107 developed T2DM and 355 subjects did not develop the disease. The 
      plasma levels of 24 miRNAs were measured at baseline by qRT-PCR. The risk of T2DM 
      was evaluated by Cox regression analysis based on the plasma levels of the miRNAs 
      at baseline and according to the dietary intervention. Finally, pathways analyses 
      were carried out to identify target genes regulated by the miRNAs studied and 
      cellular processes which could be associated with T2DM development. RESULTS: Cox 
      regression analyses showed that patients with low plasma levels of miR-145 at 
      baseline showed a higher risk of developing T2DM after consumption of an LFHCC 
      diet. In addition, patients with low levels of miR-29a, miR-28-3p and miR-126 and 
      high plasma levels of miR-150 at baseline showed a higher risk of developing T2DM 
      after consumption of the Med diet. Finally, pathways analysis showed an 
      interaction of miR-126 and miR-29a in the modulation of FoxO, TNF-alpha, PI3K-AKT, 
      p53 and mTOR signaling, associated with T2DM development. CONCLUSION: Our results 
      suggest that circulating miRNAs could be used in clinical practice as a new tool 
      for selecting the most suitable diet to prevent type 2 diabetes mellitus 
      development in patients with cardiovascular disease. CLINICAL TRIALS NUMBER: 
      NCT00924937.
CI  - Copyright (c) 2020 Elsevier Ltd and European Society for Clinical Nutrition and 
      Metabolism. All rights reserved.
FAU - Jimenez-Lucena, Rosa
AU  - Jimenez-Lucena R
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Alcala-Diaz, Juan Francisco
AU  - Alcala-Diaz JF
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Roncero-Ramos, Irene
AU  - Roncero-Ramos I
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Lopez-Moreno, Javier
AU  - Lopez-Moreno J
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Camargo, Antonio
AU  - Camargo A
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Gomez-Delgado, Francisco
AU  - Gomez-Delgado F
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Quintana-Navarro, Gracia M
AU  - Quintana-Navarro GM
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Vals-Delgado, Cristina
AU  - Vals-Delgado C
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Rodriguez-Cantalejo, Fernando
AU  - Rodriguez-Cantalejo F
AD  - Biochemical Laboratory, Reina Sofia University Hospital, Cordoba, Spain.
FAU - Luque, Raul M
AU  - Luque RM
AD  - IMIBIC/Reina Sofia University Hospital, University of Cordoba and CIBER 
      Fisiopatologia de la Obesidad y la Nutricion (CIBEROBN), Instituto de Salud 
      Carlos III, Madrid, Spain; Department of Cell Biology, Physiology, and 
      Immunology, University of Cordoba, Cordoba, Spain. Agrifood Campus of 
      International Excellence (ceiA3), Cordoba, Spain.
FAU - Delgado-Lista, Javier
AU  - Delgado-Lista J
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Ordovas, Jose M
AU  - Ordovas JM
AD  - Nutrition and Genomics Laboratory, J.M, US Department of Agriculture Human 
      Nutrition Research Center on Aging, Tufts University, Boston, MA, USA; Centro 
      Nacional de Investigaciones Cardiovasculares, Madrid, Spain; IMDEA Food 
      Institute, CEI UAM+CSIC, Madrid, Spain.
FAU - Perez-Martinez, Pablo
AU  - Perez-Martinez P
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Rangel-Zuniga, Oriol Alberto
AU  - Rangel-Zuniga OA
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Lopez-Miranda, Jose
AU  - Lopez-Miranda J
AD  - Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides 
      Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University 
      Hospital, University of Cordoba. Cordoba. Spain; CIBER Fisiopatologia de la 
      Obesidad y la Nutricion (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. 
      Electronic address: jlopezmir@uco.es.
LA  - eng
SI  - ClinicalTrials.gov/NCT00924937
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200715
PL  - England
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
RN  - 0 (Biomarkers)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/blood/*diet therapy
MH  - Diabetes Mellitus, Type 2/etiology/*prevention & control
MH  - *Diet, Fat-Restricted
MH  - *Diet, Mediterranean
MH  - Female
MH  - Humans
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Single-Blind Method
MH  - Young Adult
OTO - NOTNLM
OT  - Biomarkers
OT  - CORDIOPREV
OT  - Diet
OT  - Prevention
OT  - Type 2 diabetes mellitus
OT  - microRNAs
COIS- Conflict of Interest None of the authors has any conflict of interest that could 
      affect the performance of the work or the interpretation of the data.
EDAT- 2020/07/30 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/07/30 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/06/30 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - S0261-5614(20)30350-2 [pii]
AID - 10.1016/j.clnu.2020.06.035 [doi]
PST - ppublish
SO  - Clin Nutr. 2021 Mar;40(3):1028-1038. doi: 10.1016/j.clnu.2020.06.035. Epub 2020 
      Jul 15.